Cyclosporine
- Generic Name
- Cyclosporine
- Brand Names
- Cequa, Gengraf, Neoral, Restasis, Sandimmune, Verkazia, Vevye, Ikervis
- Drug Type
- Small Molecule
- Chemical Formula
- C62H111N11O12
- CAS Number
- 59865-13-3
- Unique Ingredient Identifier
- 83HN0GTJ6D
- Background
Cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions. It is isolated from the fungus Beauveria nivea. Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novartis (previously known as Sandoz).
- Indication
Cyclosporine is approved for a variety of conditions. Firstly, it is approved for the prophylaxis of organ rejection in allogeneic kidney, liver, and heart transplants. It is also used to prevent bone marrow transplant rejection. For the above indications, cyclosporine can be used in conjunction with azathioprine and corticosteroids. Finally, cyclosporine can be used in patients who have chronic transplant rejection and have received previous immunosuppressive therapy and to prevent or treat graft-versus-host disease (GVHD).
Secondly, cyclosporine is used for the treatment of patients with severe active rheumatoid arthritis (RA) when they no longer respond to methotrexate alone. It can be used for the treatment of adult non-immunocompromised patients with severe, recalcitrant, plaque psoriasis that have failed to respond to at least one systemic therapy or when systemic therapies are not tolerated or contraindicated. The ophthalmic solution of cyclosporine is indicated to increase tear production in patients suffering from keratoconjunctivitis sicca. In addition, cyclosporine is approved for the treatment of steroid dependent and steroid-resistant nephrotic syndrome due to glomerular diseases which may include minimal change nephropathy, focal and segmental glomerulosclerosis or membranous glomerulonephritis.
A cyclosporine ophthalmic emulsion is indicated in the treatment of vernal keratoconjunctivitis in adults and children.
Off-label, cyclosporine is commonly used for the treatment of various autoimmune and inflammatory conditions such as atopic dermatitis, blistering disorders, ulcerative colitis, juvenile rheumatoid arthritis, uveitis, connective tissue diseases, as well as idiopathic thrombocytopenic purpura.
- Associated Conditions
- Atopic Dermatitis, Bone Marrow Transplant Rejection, Chronic transplant rejection, Connective Tissue Disorders, Dry Eyes, Graft-versus-host Disease (GVHD), Heart Transplant Rejection, Immune Thrombocytopenia (ITP), Interstitial Cystitis, Juvenile Idiopathic Arthritis (JIA), Kidney Transplant Rejection, Liver Transplant Rejection, Lupus Nephritis, Nephrotic Syndrome, Ocular Rosacea, Rheumatoid Arthritis, Severe Ulcerative Colitis, Steroid Dependent Nephrotic Syndrome, Steroid Resistant Nephrotic Syndrome, Uveitis, Vernal Keratoconjunctivitis, Blistering disorder, Refractory Ulcerative colitis, Severe Psoriasis, Severe, active Rheumatoid arthritis, Severe, recalcitrant Plaque psoriasis, Suppressed tear production
A Research Study To See How Well an Eye Drop, SURF-100 (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination), Works and What Side Effects There Are in Subjects With Dry Eye Disease
- Conditions
- Dry Eye Disease
- Interventions
- Drug: Mycophenolic Acid 0.1%Drug: Mycophenolic Acid 0.3%
- First Posted Date
- 2021-02-02
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Surface Ophthalmics, Inc.
- Target Recruit Count
- 349
- Registration Number
- NCT04734197
- Locations
- 🇺🇸
North Valley Eye Medical Group Inc., Mission Hills, California, United States
🇺🇸LoBue Laser and Eye Medical Center, Murrieta, California, United States
🇺🇸Martel Eye Medical Group, Rancho Cordova, California, United States
Topical Cyclosporine A for the Treatment of Dry Eye: A Randomized Clinical Study
- First Posted Date
- 2021-01-19
- Last Posted Date
- 2021-01-19
- Lead Sponsor
- Alexandria University
- Target Recruit Count
- 40
- Registration Number
- NCT04714099
Topical Immuonosuppressant Drugs in Spring Catarrh
- Conditions
- Vernal Keratoconjunctivitis
- Interventions
- First Posted Date
- 2021-01-12
- Last Posted Date
- 2021-01-12
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 180
- Registration Number
- NCT04705584
- Locations
- 🇪🇬
Assiut University Hospital, Assiut, Egypt
MSC for Treatment of cGVHD After Allo-HSCT
- Conditions
- Chronic Graft-versus-host Disease
- Interventions
- First Posted Date
- 2020-12-31
- Last Posted Date
- 2020-12-31
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 152
- Registration Number
- NCT04692376
- Locations
- 🇨🇳
Department of Hematology,Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
A Single-arm Trial of Prophylactic Tocilizumab for Acute GVHD Prevention After Haploidentical HSCT.
- Conditions
- LeukemiaGraft-versus-host-disease
- Interventions
- First Posted Date
- 2020-12-29
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- Yi Luo
- Target Recruit Count
- 46
- Registration Number
- NCT04688021
- Locations
- 🇨🇳
The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
Ikervis for DED Due to GVHD Post Allo-HSCT
- First Posted Date
- 2020-11-19
- Last Posted Date
- 2020-11-19
- Lead Sponsor
- Singapore Eye Research Institute
- Target Recruit Count
- 40
- Registration Number
- NCT04636918
- Locations
- 🇸🇬
Singapore Eye Research Institute, Singapore, Singapore
Effect of Ciclosporin Eyedrops on Sjögren Syndrome
- Conditions
- Dry Eye Syndromes
- Interventions
- First Posted Date
- 2020-10-22
- Last Posted Date
- 2021-04-08
- Lead Sponsor
- Hospital Hietzing
- Target Recruit Count
- 12
- Registration Number
- NCT04597762
- Locations
- 🇦🇹
Augenabteilung - Klinik Hietzing, Vienna, Austria
Evaluation of the Clinical Outcome of Cyclosporine Short Infusion Versus Continuous Infusion Post Allogenic Stem Cell Transplantation
- Conditions
- Allogenic Bone Marrow Transplantation
- Interventions
- First Posted Date
- 2020-10-05
- Last Posted Date
- 2023-02-01
- Lead Sponsor
- Shaymaa Mohammed El-Awady
- Target Recruit Count
- 31
- Registration Number
- NCT04575779
- Locations
- 🇪🇬
Shaymaa Mohammed Mohammed Youssef El-Awady, Cairo, Egypt
Comparing Treatment of Dry Eye With Intracanalicular Dexamethasone, Restasis, and/or Lotemax
- Conditions
- Dry Eye
- Interventions
- First Posted Date
- 2020-09-21
- Last Posted Date
- 2023-10-11
- Lead Sponsor
- Thomas Chester, OD
- Target Recruit Count
- 30
- Registration Number
- NCT04555694
- Locations
- 🇺🇸
Cleveland Eye Clinic, Brecksville, Ohio, United States
A Study Comparing Haploidentical Hematopoietic Stem Cell Transplantations (HSCTs) From Young Non-first-degree and Older First-degree Donors in Hematological Malignancies
- Conditions
- Leukemia
- Interventions
- First Posted Date
- 2020-09-14
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- First Affiliated Hospital of Zhejiang University
- Target Recruit Count
- 176
- Registration Number
- NCT04547049
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Soochow, China
🇨🇳Xinqiao Hospital, State Key Laboratory of Trauma and Chemical Poisoning, Army Medical University, Chongqing, China
🇨🇳The First Affiliated Hospital of Ningbo University, Ningbo, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.